A step closer to dental caries prevention: Successful completion of phase 1 clinical study enrollment for C16G2
C3 Jian, Inc., a private company focused on providing improved oral health care, announced the successful completion of Phase 1 study enrollment for its novel peptide therapeutic, C16G2, which has demonstrated activity selectively targeting Streptococcus mutans, a cavity-causing organism. The current indication sought for C16G2 is prevention of dental caries in adults, adolescents, and pediatrics.
LOS ANGELES, Feb. 19, 2013 (GLOBE NEWSWIRE) — C3 Jian, Inc., a private company focused on providing improved oral healthcare, announced the successful completion of Phase 1 study enrollment for its novel peptide therapeutic, C16G2.
C16G2 is a synthetic peptide derived from C3 Jian's proprietary, pheromone signaling platform technology referred to as STAMPS (Specifically Targeted Antimicrobial Peptides). C16G2 has demonstrated activity selectively targeting Streptococcus mutans, a cavity-causing
organism. The current indication sought for C16G2 is prevention of dental caries in adults, adolescents, and pediatrics. Dental caries, commonly known as tooth decay or a cavity, is rated the most common chronic childhood disease according to the U.S. Surgeon General. In the United States alone, over $100 billion is spent annually on oral health expenditures. A majority of these expenses is directly related to dental caries.
RELATED |Dental calculus
RELATED |And you thought dental plaque was bad: preventing evolution of biofilms
"Completion of enrollment for the Phase 1 trial is a significant achievement for C3 Jian and expected to provide clinical information contributing to the ongoing and dynamic development program for C16G2," said Laura A. Navalta, C3 Jian's vice president of clinical operations.
The double-blind Phase 1 clinical trial included a dose escalation period and focused on evaluating the safety, pharmacokinetics, and
microbiology of C16G2 administered in a single oral dose in mouth rinse to healthy adult subjects. This study was conducted at New York
University, Bluestone Center for Clinical Research. Mark Wolff, DDS, PhD, professor and chair of the Department of Cariology & Comprehensive Care at NYU College of Dentistry, served as the principal investigator of the study. This study is C3 Jian's first Phase 1 clinical trial.
"Our collaboration with Dr. Wolff and Bluestone has resulted in a quality run program and we are pleased with the progress of our first
clinical trial. Over the next several months we will obtain and assess the data that will help us map the future advancement of C16G2. With
appropriate results, it is our hope to begin Phase 2 studies in 2014," said Todd R. Patrick, C3 Jian's president and CEO.
About C3 Jian, Inc. — C3 Jian is a clinical-stage biotechnology company developing and commercializing novel products to diagnose, treat, and prevent diseases related to oral health. C3 is advancing targeted proprietary solutions, which can offer more selective, efficacious, and safer treatment modalities for dental applications. The company's platform cell signaling technology has potential applications beyond oral health and may impact a variety of diseases and disorders particularly related to bacterial and fungal infections. C3 Jian is based in Los Angeles, Calif. For more information about the company, please visit their website.